Boston Scientific is reaping the rewards from the energised PFA market opportunity in atrial fibrillation treatment.

Farapulse, Boston Scientific’s pulsed field ablation product, fueled year-over-year growth of nearly 171% in the fourth ...

Boston Scientific apparently knows a good bet when it sees one. | That includes treating more than 200,000 patients with the irregular heartbeat known as atrial fibrillation—and the sum more than ...

As pulsed field ablation transformed the electrophysiology market over the last year, Boston Scientific Corp. emerged as the ...

Minnesota system treating atrial fibrillation helped sustain Boston Scientific’s streak of bullish results as the company ...

Boston Scientific Corp (BSX) reports impressive Q4 2024 results with 22.4% revenue growth and a 26% increase in adjusted EPS, ...

Boston Scientific (NYSE: BSX) shares ticked up slightly before hours today on fourth-quarter results that beat the consensus ...

Medical device maker Boston Scientific forecast annual profit above Wall Street estimates on Wednesday, banking on steady demand for its heart devices.

The company states: “Boston Scientific (BSX) announced data supporting the use of the FARAPULSE Pulsed Field Ablation System* and the WATCHMAN FLX Left Atrial Appendage Closure Device ...

Boston Scientific Corporation ( NYSE: BSX) Q4 2024 Earnings Conference Call February 5, 2025 8:00 AM ET Jonathan Monson - SVP, IR Michael Mahoney - Chairman and CEO Daniel Brennan - EVP and CFO ...

Boston Scientific posted Q4 revenue of $4.56 billion, surpassing estimates. The company forecasts 2025 sales growth of up to 14.5% and EPS of $2.80-$2.87.

"US pulsed field ablation market revenue exceeds $500m in 2024" was originally created and published by Medical Device ...